KKR takes Integer private for $5.7bn as device manufacturing growth slows

Integer Holdings Corporation agreed to be acquired by KKR in an all-cash transaction valued at approximately $5.7 billion, transferring one of the world’s largest medical-device contract development and manufacturing organizations into private ownership. The New York Stock Exchange-listed company, which trades under $ITGR, said shareholders will receive $127 for each outstanding share. The offer represents a 51.8% premium to Integer’s closing price on April 29, the final trading day before the company announced a strategic review, and a 28.8% premium to its 30-day volume-weighted average price through July 31. The transaction arrives as Integer’s second-quarter sales and adjusted EBITDA decline because of product transitions, portfolio exits and weaker operating leverage. KKR is effectively paying for the company’s long-term position in cardiovascular, neuromodulation and cardiac-rhythm technologies rather than relying on an immediate acceleration in reported earnings.

Integer’s board unanimously approved the agreement and recommended that shareholders support it. The acquisition is expected to close before the end of 2026, subject to shareholder approval, regulatory clearance and other customary conditions, and it is not contingent on KKR obtaining financing.

KKR will finance the acquisition through equity provided by its core private-equity funds and committed debt financing arranged by Citi, KKR Capital Markets, Barclays, UBS and Jefferies. Once the deal closes, Integer’s shares will stop trading on the New York Stock Exchange.

Why KKR is paying a 52% premium despite weaker Integer quarterly earnings

Integer’s $127 offer price is designed to compensate shareholders for surrendering future participation in the company’s growth. The premium is particularly large when measured against the April 29 share price, although the comparison predates the public disclosure that Integer was evaluating strategic alternatives.

The more current comparison is the 28.8% premium to Integer’s 30-day volume-weighted average price through July 31. That measure captures trading after the strategic review became public and therefore includes some market expectation that the company could be sold.

Integer shares traded near $124.47 on August 3, approximately 2% below the agreed consideration. The remaining discount reflects the time required to complete the acquisition and the possibility, however limited the market may consider it, that shareholder, regulatory or other closing conditions are not satisfied.

The approximately $5.7 billion enterprise value equals roughly 14.2 times Integer’s 2025 adjusted EBITDA of $402 million. That calculation provides a broad indication of valuation, but it does not account for changes in earnings, debt or cash after the end of 2025 and should not be interpreted as the definitive transaction multiple used by KKR.

The valuation appears to reflect the durability of medical-device outsourcing rather than the latest quarter alone. Integer supplies engineering, components, subassemblies and finished devices used in cardiovascular procedures, cardiac-rhythm management and neuromodulation, markets supported by aging populations, chronic disease and continued medical-technology innovation.

Manufacturing relationships can be difficult to replace because many components are used in regulated products that require extensive qualification, quality controls and customer validation. A device company moving production to a different supplier may need to complete technical, regulatory and supply-chain work before the new source can be used commercially.

Those barriers can create long customer relationships and recurring revenue even when individual product programs fluctuate. KKR is therefore acquiring manufacturing capability, engineering expertise and customer integration that would be costly and time-consuming to reproduce organically.

What Integer’s weaker second quarter reveals about the timing of the deal

Integer reported second-quarter sales of $464 million, a decline of 2.6%, while organic sales fell 1.5%. GAAP operating income dropped 42% to $35 million, and adjusted operating income decreased 10% to $73 million.

Adjusted EBITDA declined 4% to approximately $95 million. Adjusted net income remained broadly unchanged at $55 million, while adjusted earnings per share increased 3% to $1.60 because of share-count and adjustment effects.

The quarter was not evidence of a broad collapse in medical-device demand. Integer attributed much of the pressure to previously disclosed product transitions, the exit from portable medical products and a mix of restructuring, impairment and technology-system expenses.

Cardio and Vascular sales declined 2.3% to $280 million as new electrophysiology products affected comparative volumes. Cardiac Rhythm Management and Neuromodulation sales increased 1% to approximately $174 million, while Other Markets revenue fell 43% to $10 million, mainly because of the planned Portable Medical exit.

The product transitions help explain why the timing may appeal to KKR. A private owner can invest through a temporary period of weaker reported growth without facing the same quarterly market pressure applied to a public company.

Integer had previously expected selected new-product headwinds to restrain 2026 performance before organic growth returned to approximately two percentage points above its underlying markets in 2027. The company has withdrawn that outlook because of the pending transaction, meaning shareholders will no longer receive a formal public forecast against which to evaluate the recovery.

The withdrawn forecast also reduces the relevance of comparing the purchase price only with current earnings. KKR’s return will depend on whether Integer can restore organic growth, improve manufacturing productivity and expand margins after the known product pressures ease.

The company’s 2025 performance demonstrated the underlying potential. Annual sales increased 8% to $1.85 billion, adjusted operating income rose 13% to $321 million and adjusted EBITDA increased 12% to $402 million.

Cardio and Vascular revenue grew 17% during 2025, supported by new electrophysiology programs, acquisitions and neurovascular demand. That earlier growth provides a stronger indication of the platform KKR believes it is buying than the temporary decline recorded during the latest quarter.

Why Integer’s manufacturing platform is strategically valuable to KKR

Integer operates as a development and manufacturing partner for companies producing medical devices rather than relying primarily on products sold under its own consumer-facing brand. Its capabilities range from precision components and coatings to catheters, guidewires, implantable batteries, capacitors and finished medical systems.

The Cardio and Vascular portfolio supports interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, oncology, electrophysiology and other procedures. Integer’s manufacturing capabilities include laser-cut components, catheter shafts, specialized coatings, guidewires, delivery systems and sensor integration.

Its Cardiac Rhythm Management and Neuromodulation operations produce technologies used in pacemakers, defibrillators and implantable stimulation systems. Customers depend on consistent product quality because failures in implantable or minimally invasive devices can create significant patient, regulatory and financial consequences.

Integer owned 731 United States and international patents at the end of 2025, although the company said no individual patent or technology was material to the business as a whole. The broader competitive advantage comes from combining intellectual property with engineering knowledge, manufacturing processes, regulatory experience and customer relationships.

The company employed approximately 11,000 people at the end of 2025. Its workforce was distributed across the United States, Mexico, Ireland, the Dominican Republic, Uruguay, Malaysia and several smaller locations, giving Integer access to engineering talent and lower-cost manufacturing while remaining close to major medical-device customers.

That global structure can improve cost competitiveness and production flexibility, but it also creates operational complexity. Products may be qualified at specific facilities, limiting Integer’s ability to move production quickly if a plant experiences equipment failure, labor disruption, natural disaster or regulatory problems.

KKR said private ownership will provide additional flexibility and long-term capital for capacity, technology, innovation and talent. That strategic rationale is credible because medical-device customers increasingly seek manufacturing partners capable of supporting a product from initial design through commercialization and high-volume production.

The transaction may also allow Integer to pursue acquisitions without having each investment judged against near-term public earnings expectations. The company expanded its coatings capabilities during 2025 through Precision Coating, VSi Parylene and selected Biocoat assets, demonstrating how targeted acquisitions can broaden the technologies offered to existing customers.

How acquisition debt could reshape Integer’s financial risk after the sale

Integer entered the transaction with substantial existing leverage. Total debt reached approximately $1.24 billion at the end of the second quarter, while net debt was approximately $1.24 billion and the leverage ratio increased to 3.2 times adjusted EBITDA.

Debt had already risen during 2025 to finance acquisitions, convertible-note costs and share repurchases. Net debt ended that year at approximately $1.19 billion, equal to three times adjusted EBITDA.

KKR has not publicly disclosed the final division between sponsor equity and new acquisition debt. The transaction announcement confirms that committed debt financing will be used, meaning Integer’s post-closing capital structure is likely to include financing beyond the debt currently reported by the company.

Private-equity leverage can increase investor returns when earnings and cash flow grow because the acquired company repays debt over time. It can also reduce financial flexibility if sales weaken, interest costs rise or customers delay product launches.

Integer requires continuing investment in manufacturing equipment, information systems and facility upgrades. Before announcing the transaction, the company expected 2026 capital expenditure of between $95 million and $105 million, following $91 million of spending during 2025.

Those expenditures cannot be eliminated simply to accelerate debt repayment. Medical-device manufacturing requires reliable equipment, validated processes and quality systems, and insufficient investment could lead to production problems, customer losses or regulatory concerns.

The company also implemented a global enterprise-resource-planning system and manufacturing realignment initiatives that created additional expenses during 2026. These programs could improve efficiency once completed, but they require management attention and cash before the full benefits are visible.

KKR’s challenge will be to improve margins without weakening the quality and reliability that make Integer strategically valuable. Excessive cost reduction would be particularly risky in a regulated manufacturing business where customers place a premium on consistent execution.

The absence of a financing contingency reduces the risk that KKR can abandon the transaction solely because debt markets become less attractive. It does not eliminate the longer-term burden that acquisition financing could place on Integer after the deal closes.

What shareholders and Integer employees should watch before the acquisition closes

Integer shareholders must approve the merger before it can be completed. The company will file a proxy statement containing additional information about the board’s strategic review, financial-advisor analysis, executive interests, merger terms and the risks associated with the transaction.

Those disclosures will be important because the initial announcement provides only a high-level explanation of why the board selected KKR. Investors will need to assess which alternatives were considered, how the $127 price was evaluated and whether any contractual provisions could affect the board’s response to a superior proposal.

Shareholders receive certainty in the form of cash and avoid the risk that Integer’s product headwinds last longer than expected. They also surrender any upside above $127 if new programs, margin improvements or future acquisitions create substantially greater value under KKR’s ownership.

The approximately 2% trading discount to the offer price indicates that the market currently assigns a high probability to completion while still accounting for closing time and deal risk. That spread could narrow as shareholder and regulatory approvals are obtained, or widen if unexpected obstacles emerge.

KKR intends to establish a broad-based employee ownership and engagement program after closing. The firm said its portfolio companies have awarded equity value to more than 200,000 non-senior employees since 2011, although the size, eligibility and potential value of the Integer program have not yet been disclosed.

Employee ownership can align workers with operational improvement and long-term value creation. Its practical impact will depend on vesting rules, distribution across locations, performance conditions and what happens when KKR eventually sells or relists the company.

Integer’s workforce is central to the acquisition thesis because specialized manufacturing knowledge cannot be replaced as easily as physical machinery. Retaining engineers, technicians, regulatory specialists and plant employees will be necessary if KKR expects to expand capacity and restore above-market growth.

The proposed acquisition gives shareholders a substantial immediate premium and gives KKR a durable medical-technology manufacturing platform. The longer-term outcome will be determined by whether private ownership provides enough investment freedom to accelerate innovation without allowing acquisition leverage to constrain the quality, capacity and reliability on which Integer’s customers depend.

Key takeaways from KKR’s $5.7 billion Integer acquisition

• KKR agreed to acquire Integer Holdings Corporation for approximately $5.7 billion in enterprise value and pay shareholders $127 per share in cash.
• The offer represents a 51.8% premium to Integer’s April 29 closing price and a 28.8% premium to its 30-day volume-weighted average price through July 31.
• Integer shares traded approximately 2% below the offer price on August 3, indicating a relatively narrow market assessment of closing and timing risk.
• The transaction values Integer at roughly 14.2 times its 2025 adjusted EBITDA of $402 million, although current debt and earnings will affect the final economic multiple.
• Second-quarter sales declined 2.6% to $464 million, while adjusted EBITDA fell 4% to $95 million because of product transitions, portfolio exits and operating pressures.
• Integer’s long-term value is tied to specialized cardiovascular, neuromodulation and cardiac-rhythm manufacturing capabilities that can be difficult for customers to replace.
• The company employed approximately 11,000 people across a global manufacturing network and owned 731 patents at the end of 2025.
• Integer entered the deal with approximately $1.24 billion of net debt and leverage of 3.2 times adjusted EBITDA, before incorporating KKR’s acquisition financing.
• The agreement is not subject to a financing contingency, but it still requires Integer shareholder approval, regulatory clearance and satisfaction of other closing conditions.
• The outlook for $ITGR shareholders now depends primarily on transaction completion, while KKR’s return will depend on restoring organic growth without allowing leverage or cost reductions to weaken manufacturing execution.